Related Business Topics
Latest Headlines
Reuters - Nov. 23, 2009, 5:07 AM
- Primary study objectives include evaluation of safety and tolerability, as well as selection of a recommended dose for Phase 2 trials - - Continued progress on IAP inhibitor program - ROCKVILLE, Md. & MONTREAL--(Business Wire)-- Human Genome Sciences, ...
Forbes.com - Nov. 17, 2009, 12:51 PM
DECODEGENETICS/ (UPDATE 3):UPDATE 3- * To sell substantially all of its assets * Lists assets of $69.9 million, debt of $313.9 million * Shares plunge around 83 percent (Recasts with CEO interview, share drop, background) WASHINGTON (Reuters) - Iceland's ...
Reuters - Nov. 17, 2009, 12:32 PM
By Ben Hirschler WASHINGTON (Reuters) - Iceland's Decode Genetics Inc, a pioneer in genetic research, has filed for bankruptcy protection, weighed down by debts after 13 years of failing to make a profit. Shares in the group plunged around 83 percent on ...
Reuters - Nov. 16, 2009, 5:49 AM
* Gets complete response for raxibacumab BLA * Says FDA requested additional information * Says plans to address the current questions Nov 16 (Reuters) - Human Genome Sciences Inc (HGSI.O) said the U.S. health regulators denied to approve its ...
Forbes.com - Nov. 16, 2009, 4:40 AM
Nov 16 (Reuters) - Human Genome Sciences Inc: * Receives complete response letter from FDA for Raxibacumab Biologics license application * Says FDA request additional information needed to complete the review of a bla * Says in certain respects, letter ...
Reuters - Nov. 12, 2009, 12:36 PM
NEW YORK (Reuters) - GlaxoSmithKline Plc (GSK.L) said on Thursday it expects its experimental lupus drug Benlysta to be a 'very major' product and contribute meaningfully to the company's bottom line. Glaxo and partner Human Genome Sciences Inc (HGSI.O) ...
Forbes.com - Nov. 4, 2009, 11:47 AM
ROCKVILLE, Md. 'Zyngenia's technology platform, developed by Carlos Barbas of The Scripps Institute, is very compelling due to its ability to create biologics that are single protein-combination therapeutics in a manner that is likely to be ...
Times Online - Nov. 2, 2009, 6:58 PM
View video and Need to Know interactive heatmap Economics Manufacturing sector: Official figures showed that manufacturing has expanded unexpectedly at its fastest pace in two years, as the Chartered Institute of Purchasing and Supplys latest reading ...
Forbes.com via MSN Money - Nov. 2, 2009, 11:39 AM
Human Genome Sciences( HGSI - news - people ): There was a predictable investor response after results of late-stage clinical trials on Benlysta paved the way for the first new lupus treatment for a half decade. Shares in the company surged to a high of ...
ABC News - Nov. 2, 2009, 11:11 AM
BOSTON/LONDON (Reuters) - Human Genome Sciences Inc said its experimental lupus drug Benlysta eased symptoms in more than 43 percent of patients who took it in a clinical trial, paving the way for approval of the first new treatment for the disease in 50 ...
0-9 |
A |
B |
C |
D |
E |
F |
G |
H |
I |
J |
K |
L |
M |
N |
O |
P |
Q |
R |
S |
T |
U |
V |
W |
X |
Y |
Z
H
